生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | dBET6 is an optimized and highly cell-permeable chemical degrader of BET bromodomain proteins, based on PROTAC. Incubation with dBET6 at concentration ranging in 0.1nM-1μM for 3h led to dose-dependent degradation of BRD2, BRD3, BRD4 via proteasome in cells. Treatment with 100 nM dBET6 for 1h caused degradation of BRD4 relying on E3 ubiquitin ligase CRBN and subsequent downregulation of c-MYC and induction of apoptosis in T-ALL (T cell acute lymphoblastic leukemia) cells. Intraperitoneal injection with dBET6 at dose of 7.5mg/kg, BID, for 18 days significantly inhibited tumor growth in SUPT11 xenograft mice with degradation of BRD4 in vivo, as well as exhibited a significant survival benefit in MOLT4 xenograft mice compared to vehicle control or JQ1-treated group. Degradation of BET by dBET6 causes a collapse of global elongation that phenocopies CDK9 inhibition, attenuating p-TEFb activity independent of recruitment with a specific downregulation of Ser2 phosphorylation observed[1]. | ||
作用机制 | dBET6 is chemical degrader of BET bromodomain proteins based on PROTAC and led a collapse of global elongation that phenocopies CDK9 inhibition.[1] |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.19mL 0.24mL 0.12mL |
5.94mL 1.19mL 0.59mL |
11.89mL 2.38mL 1.19mL |
参考文献 |
---|